A Phase 2 interventional study of Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome and Vehicle Control in Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders, sponsored by University of Illinois Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by University of Illinois Chicago · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.
This study's planned enrollment of 24 is above the median of 20 across 23 interventional studies indexed under Limbal Stem Cell Deficiency.
Browse Limbal Stem Cell Deficiency studies →University of Illinois Chicago is the lead sponsor of 31 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular Health
Study Procedures
Exclusion Criteria:
Ocular Health
Study Procedures
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome for Topical Eye Drop
Drug: Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome
Vehicle (unconditioned media)
Other: Vehicle Control
Eye Drops
Eye Drops
Improvement of Corneal Epithelial Barrier and/or Integrity (Efficacy Outcome)
Proportion of subjects with improved epithelial barrier and/or integrity from baseline to DAY 56 as determined by the investigator on slit lamp examination: · Improved epithelial barrier, defined as ³ 50 % improvement in corneal fluorescein staining score using NEI grading scale · Improved epithelial integrity, defined as complete closure of persistent epithelial defect, measured with ImageJ on slit lamp images
Time frame: Baseline to Day 56
Visual Acuity
Percent change in best-corrected distance visual acuity from baseline to DAY 56 as measured using standard ETDRS protocols
Time frame: Baseline to Day 56
Corneal staining and NEI grading
Grading of fluorescein staining of the cornea Minimum score = 0 Maximum score = 15 Lower score is better
Time frame: Baseline to Day 70
Ocular Surface Parameters
Changes in ocular surface disease index (OSDI) from baseline to DAY 56 and DAY 70 Minimum value = 0 Maximum value = 100 Lower value is better
Time frame: Baseline to Day 70
Corneal Epithelial Thickness
Percent change in corneal epithelial thickness from baseline to DAY 56 and DAY 70, as measured by anterior segment OCT (AS-OCT)
Time frame: Baseline to Day 70
Subject Symptoms
Changes in ocular discomfort visual analog scale (VAS) 0 - 100, where 0 is no discomfort and 100 the worst discomfort, from baseline to DAY 70
Time frame: Baseline to Day 70
Time to epithelial healing
Time of improvement of epitheliopathy
Time frame: Baseline to Day 70
Corneal Opacities/Scars
Change in the size of corneal opacities and scars (if present) from baseline to DAY 56 as documented by slit lamp photographs
Time frame: Baseline to Day 56
Corneal vascularization
Change in corneal vascularization on slit lamp photographs from baseline to DAY 56
Time frame: Baseline to Day 56
Conjunctival injection
Change in conjunctival injection on slit lamp examination from baseline to DAY 56
Time frame: Baseline to Day 56
Subbasal corneal nerve density
Changes in subbasal corneal nerve density on confocal microscopy from baseline to Day 56
Time frame: Baseline to Day 56
Ocular Surface Parameters
Changes in Lissamine green staining from baseline to DAY 56 and DAY 70
Time frame: Baseline to Day 70
Ocular Surface Parameters
Changes in anesthetic Schirmer's test from baseline to DAY 56 and DAY 70
Time frame: Baseline to Day 70
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Mar 2026 → Dec 2026 and completion Jun 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois Chicago